Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Glybera

This page shows the latest Glybera news and features for those working in and with pharma, biotech and healthcare.

NICE backs GSK’s €594k gene therapy for rare disease

NICE backs GSK’s €594k gene therapy for rare disease

Strimvelis was approved by the EMA in 2016 - the second gene therapy to get a green light anywhere in the world after UniQure’s $1m Glybera (alipogene tiparvovec) product for lipoprotein

Latest news

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    UniQure charged $1m for its Glybera (alipogene tiparvovec) product for lipoprotein lipase deficiency (LPLD) - the first gene therapy approved in Europe - but that product was withdrawn from the market this year

  • Spark closes on first US gene therapy approval Spark closes on first US gene therapy approval

    The first (and so far only) gene therapy to reach the market in the EU - UniQure/Chiesi's 1m-per-treatment Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency (LPLD) - was withdrawn

  • UniQure pulls first EU gene therapy UniQure pulls first EU gene therapy

    Glybera's usage has been extremely limited and we do not envision patient demand increasing materially in the years ahead.". ... The company says it has already started discussions with the European Medicines Agency (EMA) about withdrawing Glybera and

  • Pfizer buys gene therapy specialist Bamboo Pfizer buys gene therapy specialist Bamboo

    In Europe the only approved gene therapy is uniQure's lipoprotein lipase deficiency treatment Glybera, although the EU's Committee for Medicinal Products for Human Use (CHMP) recently recommended approval of

  • GSK gene therapy tops CHMP recommendations GSK gene therapy tops CHMP recommendations

    For now, GSK is not discussing its pricing plans for Strimvelis but has said it will be substantially less than the $1m charged by UniQure for Glybera (alipogene tiparvovec), currently the

More from news
Approximately 4 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    Before being pulled from the European market for safety concerns and lack of uptake, pancreatic drug Glybera cost $1m a dose.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Glybera, the expensive gene therapy developed for a small subset of patients with the rare familial lipoprotein lipase deficiency (LPLD). ... The company’s chief executive Matthew Kapusta said simply: “Glybera’s usage has been extremely limited and

  • Pharma deals in April 2015 Pharma deals in April 2015

    Following Glybera's approval in Europe for lipoprotein lipase deficiency (LPLD), uniQure, the gene therapy pioneer has announced an exclusive strategic collaboration with Bristol Myers Squibb (BMS) for its lead candidate ... Glybera's $1m cost per

  • Anticipating the future in healthcare Anticipating the future in healthcare

    As a gene therapy, Glybera is injected through a one-time course of up to 60 consecutive intramuscular injections. ... The introduction of therapies such as Glybera and Holostem will have significant implications on the healthcare ecosystem.

  • Gathering pace: adaptive pathways Gathering pace: adaptive pathways

    need for changes to its licensing framework in the wake of the approval last year of UniQure's gene therapy Glybera (alipogene tiparvovec) for lipoprotein lipase deficiency. ... Glybera was eventually approved for a narrower group of patients than

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Quick links

Infographics

Multimedia